LUCIUS 卢修斯 厄达替尼 Erdafitinib尿路上皮癌

厄达替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Erdafitinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Conpstien:
ach filr-coared tablet contaiss Endafitinib ....... 5m

LUCIUS

尿路上皮癌

LnciEada isa kinase inhibitor indicated for the trestment
sdult ostients with locally ad sanced or metastatie

PHARMACEUTICALS

guscectible FGFR3 or FOFR2 genetic alterations and
progressed during or fellowing at least one line of prio
platnuc-cestaning chemotheragy iclading witimn
months of neondiuvant or adunant platinum-certining

LuciErda

chemotheraoy
tostirn the presesce of FOFR genetic altertions in
turor specirens prorte initiation of trvatuent with
Recommended intitl dosage: 8 mg orally oncedanls

Erdafitinib Tablets

FDA批准

sith a dose increase to 9 mg dai lv ifcriteria are met.
Swrallow whole with or without faod.
ga dry place and store at 20Cto 25C

Keep medici ne out of reach of Children. Do not sdmiristet
LuciErda dering Pregnaney and Lactstion
PLEASE SEEPACKACEINSERT

5mg

Mamafactured aod Marketed by:
LUCIUS

权威认证

notgmang rillage. Xaythany district, Vientiane

28 Tablets

Warning: Tobe sold bo retail on orescrintion
ot regstered physicians only, ind os directed

Rx Only

口碑质量

适应症:
适用于治疗患有局部晚期或转移性尿路上皮癌的成年患者
推荐剂量:
起始剂量为8mg每日一次,空腹或随餐口服,在第14天和第21天
之间血磷水平低于5.5mg/dL目标值的患者,剂量增加至9mg每
日一次,直至疾病进展或无法耐受。
如果服药后发生呕吐,不可补服,下次服药仍按照原间隔时间。如
果漏服,当日内可以按量补服,下次服药仍按照原间隔时间。